These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 27823819)
1. Re: Reevaluating PSA Testing Rates in the PLCO Trial. Albers P Eur Urol; 2017 Feb; 71(2):300. PubMed ID: 27823819 [No Abstract] [Full Text] [Related]
2. Re: Reevaluating PSA Testing Rates in the PLCO Trial. Taneja SS J Urol; 2016 Oct; 196(4):1123-5. PubMed ID: 27628793 [No Abstract] [Full Text] [Related]
3. More on Reevaluating PSA Testing Rates in the PLCO Trial. Shoag JE; Mittal S; Hu JC N Engl J Med; 2016 Oct; 375(15):1500-1501. PubMed ID: 27732806 [No Abstract] [Full Text] [Related]
4. More on Reevaluating PSA Testing Rates in the PLCO Trial. Pinsky P; Prorok P N Engl J Med; 2016 Oct; 375(15):1500-1501. PubMed ID: 27732807 [No Abstract] [Full Text] [Related]
6. Reevaluating PSA Testing Rates in the PLCO Trial. Shoag JE; Mittal S; Hu JC N Engl J Med; 2016 May; 374(18):1795-6. PubMed ID: 27144870 [No Abstract] [Full Text] [Related]
7. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134 [TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK; J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007 [TBL] [Abstract][Full Text] [Related]
9. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921 [TBL] [Abstract][Full Text] [Related]
10. Re: Cui T, Kovell RC, Terlecki RP. Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature. Curr Med Res Opin 2016;32:1-7. Nyitray AG; Chiao EY Curr Med Res Opin; 2017 Feb; 33(2):315-316. PubMed ID: 27805418 [No Abstract] [Full Text] [Related]
11. Guideline of guidelines: prostate cancer screening. Loeb S BJU Int; 2014 Sep; 114(3):323-5. PubMed ID: 24981126 [No Abstract] [Full Text] [Related]
12. PSA-based screening for localised prostate cancer. Uncertain benefits, potential adverse consequences, and many outstanding questions. Prescrire Int; 2009 Oct; 18(103):225. PubMed ID: 19882799 [No Abstract] [Full Text] [Related]
13. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam. Beemsterboer PM; de Koning HJ; Kranse R; Trienekens PH; van der Maas PJ; Schröder FH J Urol; 2000 Oct; 164(4):1216-20. PubMed ID: 10992369 [TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069 [TBL] [Abstract][Full Text] [Related]
15. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332 [TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen testing and prostate cancer screening. Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192 [TBL] [Abstract][Full Text] [Related]
17. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death. Hattangadi JA; Chen MH; D'Amico AV BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982 [TBL] [Abstract][Full Text] [Related]
18. An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a Nigerian teaching hospital. Ojewola RW; Tijani KH; Jeje EA; Ogunjimi MA; Anunobi CC; Adesanya AO West Afr J Med; 2013; 32(1):8-13. PubMed ID: 23613288 [TBL] [Abstract][Full Text] [Related]
19. The Melbourne Consensus Statement on the early detection of prostate cancer. Murphy DG; Ahlering T; Catalona WJ; Crowe H; Crowe J; Clarke N; Cooperberg M; Gillatt D; Gleave M; Loeb S; Roobol M; Sartor O; Pickles T; Wootten A; Walsh PC; Costello AJ BJU Int; 2014 Feb; 113(2):186-8. PubMed ID: 24206066 [TBL] [Abstract][Full Text] [Related]
20. Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study. Walsh AL; Considine SW; Thomas AZ; Lynch TH; Manecksha RP Br J Gen Pract; 2014 Dec; 64(629):e783-7. PubMed ID: 25452543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]